PMN-MDSCs can suppress the antigen-presenting capacity of DCs by upregulating myeloperoxidase (MPO) expression, therefore limiting the ability of DCs to cross-present tumor-associated antigens (TAAs). The gene discussed is MPO; the disease is neoplasm.